Patients with low HER2 status in metastatic breast cancer can benefit from HER2-targeted treatment, potentially improving their outcomes significantly.
The VENTANA HER2 (4B5) test, also known as PATHWAY in the US, is the sole approved companion diagnostic for assessing HER2-low status in metastatic breast cancer patients.
#metastatic-breast-cancer #her2-low-status #her2-targeted-treatment #companion-diagnostic #ce-mark-approval
[
add
]
[
|
|
...
]